Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
2023-505438-85-00Phase 3Authorised
- Sponsor
- Viatris
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 47
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Selatogrel with Placebo (2 arms). Primary endpoints: Ranked efficacy endpoint after study treatment self-administration and BARC type 3 or 5 treatment-emergent bleeding. Planned start Jan 2022; status: authorised.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2023-505438-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505438-85-00.